Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FUROSEMIDE vs BUMETANIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Edema associated with heart failure, cirrhosis, renal disease,Hypertension,Hypercalcemia (off-label)
Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Treatment of hypertension (off-label)
Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
0.5-2 hours (terminal); prolonged in renal impairment (up to 9-24 hours) and hepatic cirrhosis (up to 2-4 hours).
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Furosemide is primarily metabolized via glucuronidation (by UGT1A1, UGT1A9) and to a lesser extent by CYP450 enzymes (minor).
Primarily metabolized by the liver via cytochrome P450 (CYP) enzymes, with approximately 50% excreted unchanged in urine.
Renal (50-80% unchanged; remainder as glucuronide metabolite); fecal (<2%).
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
91-99% (primarily to albumin).
Approximately 95% bound, primarily to albumin.
0.1-0.2 L/kg; increased in neonates (0.2-0.4 L/kg) and disease states (e.g., heart failure, cirrhosis).
0.15-0.25 L/kg; indicates limited extravascular distribution, consistent with high protein binding.
Oral: 50-60% (variable, 10-100% range due to food and formulation); IM: 100% (relative to IV).
Oral: approximately 80-100% (mean ~90%), with a first-pass effect of about 10-20%.
GFR 10-50 m L/min: dose unchanged; GFR <10 m L/min: avoid use or use with caution; anuric patients: contraindicated.
No specific dose adjustment for GFR >20 m L/min. For GFR 10-20 m L/min: use with caution, dose every 12-24 hours. For GFR <10 m L/min: not recommended due to lack of efficacy.
Child-Pugh A-B: no adjustment; Child-Pugh C: reduce dose by 50% and monitor response; increased risk of hypokalemia and volume depletion.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Oral: 1-2 mg/kg/dose every 6-12 hours; IV/IM: 1 mg/kg/dose every 6-12 hours; max dose: 6 mg/kg/dose. Not recommended in neonates unless critical.
IV/IM/PO: 0.015-0.1 mg/kg/dose every 6-24 hours; max 10 mg/day. For neonates: 0.01-0.05 mg/kg/dose every 12-24 hours.
Start at lowest effective dose (e.g., 20 mg orally once daily); monitor electrolytes, renal function, and volume status closely; avoid excessive diuresis.
Start at 0.5 mg once daily; titrate cautiously due to increased sensitivity and risk of electrolyte imbalance and volume depletion.
Furosemide is a potent diuretic; excessive diuresis may lead to profound electrolyte depletion, volume depletion, and circulatory collapse.
Bumetanide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose titration are required. Excessive doses can lead to hypovolemia, dehydration, and circulatory collapse.
Monitor for electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Risk of ototoxicity, especially with rapid infusion or concurrent use of other ototoxic drugs,Monitor renal function and blood pressure; caution in patients with severe hepatic cirrhosis or renal impairment,May cause photosensitivity, blood dyscrasias, and hypersensitivity reactions
Monitor fluid and electrolyte balance closely,Risk of ototoxicity, especially at high doses or with rapid infusion,May cause hyperuricemia and precipitate gout attacks,Can increase risk of digitalis toxicity due to hypokalemia
Anuria,Severe electrolyte depletion,Hypersensitivity to furosemide or sulfonamides,Hepatic coma or precoma (relative)
Anuria,Severe electrolyte depletion,Hepatic coma or pre-coma,Hypersensitivity to bumetanide or sulfonamides
Avoid excessive salt intake to prevent fluid retention and counteract diuretic effect. Limit alcohol as it can increase diuretic effect and cause dehydration. May increase potassium loss; consider potassium-rich foods (bananas, oranges, spinach) unless contraindicated (e.g., with ACE inhibitors). No specific restrictions with grapefruit juice.
No specific food restrictions, but limit salt intake to help control edema and hypertension. Avoid excessive intake of black licorice (can worsen hypokalemia). Grapefruit juice may not significantly interact, but caution with any electrolyte-altering foods. Maintain adequate fluid intake unless fluid restriction is advised by your doctor. Foods high in potassium (bananas, oranges, spinach) may be recommended if hypokalemia occurs; consult provider for individual needs.
Furosemide is pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (hydronephrosis) at high doses. Second/third trimesters: Risk of electrolyte imbalance in mother and fetus, potential for decreased placental perfusion due to maternal hypovolemia. Use only if benefit outweighs risk, especially in oligohydramnios or preeclampsia.
Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of electrolyte imbalances and hypovolemia in the fetus; possible oligohydramnios. Avoid use during pregnancy unless benefits outweigh risks.
Furosemide is excreted into breast milk in low amounts (M/P ratio approximately 2.6). Theoretical risk of electrolyte imbalance in infant. Consider using lowest effective dose and monitor infant for signs of dehydration or electrolyte disturbances.
Bumetanide is excreted into human milk in small amounts (M/P ratio not determined). Due to potential for diuresis in the infant, use with caution, especially in neonates. Consider alternative agents with more safety data.
Pregnancy increases renal clearance and volume of distribution, potentially reducing plasma furosemide levels, but dosing adjustments are not routinely recommended due to risk of hypovolemia. Use lowest effective dose and titrate based on response, with close monitoring.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, starting dose is generally unchanged; titration based on response and tolerability. Monitor for hypokalemia and hypovolemia.
Monitor urine output and electrolytes, especially potassium. Avoid use in anuria, severe electrolyte depletion, and hepatic coma. Can cause ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Sulfonamide allergy may cross-react; use caution. Loop diuretics like furosemide are effective in renal impairment, unlike thiazides.
Bumetanide is a potent loop diuretic with rapid onset and short duration. Oral bioavailability is ~80% with minimal first-pass metabolism. Onset of diuresis within 30-60 minutes, peak at 1-2 hours, duration 4-6 hours. For acute pulmonary edema, intravenous bumetanide can be given 0.5-1 mg; onset within minutes. Monitor electrolytes especially potassium, magnesium, and calcium due to increased excretion. May cause ototoxicity, especially with rapid IV administration or concurrent aminoglycosides. Use with caution in sulfonamide allergy (cross-sensitivity). In renal impairment, bumetanide may be less effective due to reduced tubular secretion; higher doses may be needed. Combine with thiazides for sequential nephron blockade in resistant edema.
Take exactly as prescribed, preferably in the morning to avoid nighttime urination.,Weigh yourself daily and report rapid weight gain or loss.,Avoid alcohol and NSAIDs as they may reduce diuretic effect or increase kidney damage.,Report hearing loss, ringing in ears, dizziness, or muscle cramps immediately.,Do not stop suddenly without consulting your doctor; may cause rebound edema.,Limit high-potassium foods if also taking ACE inhibitors or potassium-sparing diuretics.,Stay hydrated but avoid excessive fluid intake.
Take bumetanide exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not skip doses or double up on missed doses; if you miss a dose, take it as soon as you remember unless it is almost time for the next dose.,This medication can cause dehydration and electrolyte imbalances; notify your doctor if you experience excessive thirst, dry mouth, weakness, muscle cramps, or irregular heartbeat.,Avoid alcohol and over-the-counter medications, especially NSAIDs (ibuprofen, naproxen) unless approved by your doctor, as they may reduce bumetanide's effectiveness and increase kidney risk.,Stand up slowly from sitting or lying to prevent dizziness from low blood pressure.,Monitor your weight daily and report rapid weight gain or loss to your healthcare provider.
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Zaltoprofen, a nonsteroidal anti-inflammatory drug (NSAID), reduces the antihypertensive and diuretic efficacy of furosemide by inhibiting renal prostaglandin synthesis. This blockade diminishes renal blood flow and natriuretic response, potentially leading to fluid retention and diminished blood pressure control. The interaction may precipitate or exacerbate heart failure and edema in susceptible patients."
"Isoflurane, a halogenated inhalational anesthetic, can cause dose-dependent myocardial depression and systemic vasodilation, leading to decreased blood pressure and renal perfusion. Furosemide, a loop diuretic, further reduces intravascular volume and renal blood flow via inhibition of the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle. Co-administration may result in additive hypotension, acute kidney injury, and electrolyte imbalances (e.g., hypokalemia, hypomagnesemia), particularly in patients with pre-existing renal impairment or hemodynamic instability."
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits renal prostaglandin synthesis, which can reduce the efficacy of loop diuretics like bumetanide by blunting the diuretic-induced increase in renal blood flow and sodium excretion. This pharmacodynamic antagonism may result in diminished diuresis and natriuresis, potentially exacerbating fluid overload in patients with heart failure or hypertension. Clinically, this interaction may lead to suboptimal blood pressure control or worsening edema if the combination is used without dose adjustment."
"Concurrent administration of apomorphine, a dopamine agonist used for Parkinson's disease, with bumetanide, a loop diuretic, may lead to an increased risk of adverse effects, particularly hypotension and syncope. Apomorphine is known to cause orthostatic hypotension due to its vasodilatory and dopaminergic effects, which can be potentiated by bumetanide-induced volume depletion and electrolyte disturbances. This interaction can result in profound blood pressure drops, dizziness, and potential falls, especially in elderly patients or those with already compromised cardiovascular status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FUROSEMIDE vs BUMETANIDE, answered by our medical review team.
FUROSEMIDE is a Loop Diuretic that works by Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.. BUMETANIDE is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FUROSEMIDE and BUMETANIDE depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FUROSEMIDE is: Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.. The standard adult dose of BUMETANIDE is: 0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FUROSEMIDE and BUMETANIDE. The risk or severity of adverse effects can be increased when Furosemide is combined with Bumetanide. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FUROSEMIDE is classified as Category A/B. Furosemide is pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (hydronephrosis) at . BUMETANIDE is classified as Category A/B. Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.